Newbury Pharmaceuticals Ab Stock Net Income
| NEWBRY Stock | 3.44 0.08 2.38% |
Newbury Pharmaceuticals AB fundamentals help investors to digest information that contributes to Newbury Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Newbury Stock. The fundamental analysis module provides a way to measure Newbury Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Newbury Pharmaceuticals stock.
Newbury |
Newbury Pharmaceuticals AB Company Net Income Analysis
Newbury Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Newbury Pharmaceuticals AB reported net income of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-Specialty & Generic (which currently averages 0.0) industry. The net income for all Sweden stocks is 100.0% higher than that of the company.
Newbury Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Newbury Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Newbury Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newbury Pharmaceuticals by comparing valuation metrics of similar companies.Newbury Pharmaceuticals is currently under evaluation in net income category among its peers.
Newbury Fundamentals
| Return On Equity | -0.34 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.89) % | |||
| Operating Margin | (2.75) % | |||
| Current Valuation | 96.57 M | |||
| Shares Outstanding | 19.52 M | |||
| Shares Owned By Insiders | 78.64 % | |||
| Shares Owned By Institutions | 6.72 % | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 25.09 X | |||
| Revenue | 5.77 M | |||
| Gross Profit | 1.56 M | |||
| EBITDA | (15.74 M) | |||
| Book Value Per Share | 3.24 X | |||
| Target Price | 8.5 | |||
| Market Capitalization | 110.88 M | |||
| Total Asset | 86.91 M | |||
| Net Asset | 86.91 M |
About Newbury Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newbury Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newbury Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newbury Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Newbury Stock
Newbury Pharmaceuticals financial ratios help investors to determine whether Newbury Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Newbury with respect to the benefits of owning Newbury Pharmaceuticals security.